+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The role of aldosterone-antagonists in the treatment of congestive heart failure



The role of aldosterone-antagonists in the treatment of congestive heart failure



Orvosi Hetilap 146(14): 645-648



The role of aldosterone-antagonists in the treatment of congestive heart failure. Despite the advances of the treatment of congestive heart failure, nearly half of the patients diagnosed with this disease five years ago are alive today. Experimental and human studies have demonstrated, that under special pathologic condition, the heart extracts aldosterone, and aldosterone extraction in the heart stimulates increased collagen turnover culminating in ventricular remodeling. Aldosterone blockade has been shown to be effective in reducing total mortality and hospitalization for heart failure in patients with systolic left ventricular dysfunction due to chronic heart failure (RALES study with spironolactone) and in patients with systolic left ventricular dysfunction post acute myocardial infarction (EPHESUS study with eplerenone). These clinical studies have shown that mineralocorticoid receptor activation remains important despite the use of angiotensin converting enzyme inhibitor or angiotensin receptor blocking agent and a beta blocker. In the ACC/AHA (and in the European and Hungarian) guidelines for the evolution and management of chronic heart failure, the indication of spironolactone was defined of Class Ila, Level of Evidence: B in CHF of stage C. The eplerenone (in US: INSPRA) was approved for the management of CHF patients after myocardial infarction with ejection fraction < 40%. Eplerenone, compared with spironolactone, is associated with a lower incidence of gynecomastia and other sex hormone-related adverse effect (breast pain, menstrual abnormalities). The spironolactone should not be used in patients with a creatinine above 220 mikromol/l. Despite the guidelines recommendation, spironolactone has been widely used in patients without consideration of their functional class or ejection fraction, without optimization of background treatment with ACE inhibitors and beta-blockers.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 050719487

Download citation: RISBibTeXText

PMID: 15889538


Related references

The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure. Current Hypertension Reports 2(4): 378-383, 2000

Aldosterone antagonists in congestive heart failure. Current Opinion in Investigational Drugs 3(7): 1024-1028, 2002

Rationale for the use of aldosterone antagonists in congestive heart failure. Drugs 62(5): 723-731, 2002

The role of aldosterone and aldosterone-receptor antagonists in heart failure. Reviews in Cardiovascular Medicine 5(2): 71-81, 2004

Symposium on pathophysiology of congestive heart failure. 1. Relationship of renin-angiotensin-aldosterone system to cardio-renal hemodynamics on chronic congestive heart failure. Nihon Naika Gakkai Zasshi. Journal of the Japanese Society of Internal Medicine 62(12): 1609-1614, 1973

Role of aldosterone in congestive heart failure. Nihon Rinsho. Japanese Journal of Clinical Medicine 24(7): 1322-1338, 1966

Congestive heart failure: potential role of arginine vasopressin antagonists in the therapy of heart failure. Congestive Heart Failure 8(5): 251-256, 2002

The role of aldosterone in the pathogenesis of congestive heart failure. Japanese Heart Journal 8(3): 252-263, 1967

Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. American Journal of Nephrology 11(6): 441-446, 1991

Role of aldosterone on lung structural remodelling and right ventricular function in congestive heart failure. Bmc Cardiovascular Disorders 11: 72-72, 2012

Clinical studies on the role of aldosterone concerning the edema formation in chronic congestive heart failure. Japanese Circulation Journal 35(10): 1183-1202, 1971

Aldosterone antagonists in the treatment of heart failure. American Journal of Health-System Pharmacy 63(1): 49-58, 2005

The role of calcium antagonists in the therapy of congestive heart failure. Giornale Italiano di Cardiologia 28(7): 818-823, 1998

Aldosterone and prolactin responsiveness after prolonged treatment of congestive heart failure with captopril. European Journal of Clinical Pharmacology 28(1): 1-4, 1985

Inhibition of aldosterone secretion in patients with congestive heart failure role of dopamine and dopaminergic drugs. European Heart Journal 10(ABSTR SUPPL): 228, 1989